Source: Business Insider
Esperion Therapeutics just got its first heart drug approved in the US, and the CEO told Business Insider the company is pricing the cholesterol-lowering medication at around $10 per day. “Our industry was built on once-a-day pills for chronic disease,” Esperion CEO Tim Mayleben said in an interview. It’s an old-school approach that supports blockbuster hopes for Esperion’s pill. Other companies that have set higher prices for their heart drugs have fallen short in recent years. Visit Business Insider’s homepage for more stories . Esperion Therapeutics just received its first US approval on Friday, clearing the way to launch its first heart drug. The approval wraps a long, strange journey for the Ann Arbor, Michigan-based biotech and its cholesterol-lowering pill, Nexletol. Esperion was acquired by pharma giant Pfizer in 2003 for $1.3 billion. A few years later, Pfizer ditched the business as part of a massive restructuring. But Esperion’s original founder and CEO, Roger Newton, wasn’t done.